Albena Angelova

Albena Angelova, MPharm, currently serves as an IMP Manager I CTA at ARENSIA Exploratory Medicine GmbH since August 2022. Prior to this role, Albena held the position of Pharmacist at Subra pharmacies from September 2018 to August 2022. Albena obtained a Master’s degree in Pharmacy from the Faculty of Pharmacy at the Medical University of Sofia, completing studies from September 2014 to February 2020. Earlier education includes a High School Diploma in Banking and Financial Support Services from PSHSE "Dimitar Hadjivasilev," attended from September 2009 to June 2014.

Location

Sofia, Bulgaria

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


ARENSIA Exploratory Medicine GmbH

ARENSIA is a German operator of professional research clinics, dedicated to performing early phase clinical trials - Phase IB, IIA, and PROOF OF CONCEPT - with novel compounds. Our trials involve a wide range of patient populations. ARENSIA clinics are designed to enable patient's access to innovative therapies early in the drug development process. Patient's safety and comfort are of paramount importance at ARENSIA. Our facilities are strategically located within or adjacent to large university/private hospitals in the following cities: Phoenix, Arizona USA, Bucharest and Cluj-Napoca in Romania, Chisinau in Moldova, Tbilisi in Georgia, Kyiv in Ukraine and Sofia in Bulgaria. Due to its dedicated research-oriented infrastructure, ARENSIA achieves a time reduction of avg. 60% through unrivalled recruiting performance vs. typical clinical trial sites which are overcrowded by daily hospital duties, lack of staff, competition for the same populations, and long timelines for contract negotiations. The shortened time and the different setup of concentrating effort on a few ARENSIA Clinics (instead of the traditional high number of sites) lead to an overall budget reduction of 50% for a typical Phase IB/IIA PROOF OF CONCEPT trial. 93% repeat business proves that ARENSIA’s value proposition is the long-expected disruptive breakthrough in time and cost! This has allowed our continuous growth while collaborating with the leading pharmaceutical companies worldwide, numerous biotechs, as well as global CROs.


Employees

201-500

Links